Hereditary ATTR amyloidosis

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

5 events
Apr 2026WAINUA: New indication approved
FDAcompleted
Dec 2025WAINUA: New indication approved
FDAcompleted
Apr 2025WAINUA: New indication approved
FDAcompleted
Sep 2024WAINUA: New indication approved
FDAcompleted
Dec 2023WAINUA: FDA approved
FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

3 programs

FINANCIAL LANDSCAPE SUMMARY

3

Total programs

3

Open now

2

Copay cards

Copay Assistance2

Vyndaqel

Pfizer Laboratories Div Pfizer Inc

OpenContact for detailsApply ↗

Tegsedi

Ionis/AstraZeneca

OpenContact for detailsApply ↗

Patient Assistance Programs1

WAINUA

AstraZeneca Pharmaceuticals LP

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

5 FDA-approved

Tegsedi

(inotersen)Orphan drug

Ionis/AstraZeneca

Approved Oct 2018

Vyndaqel

(TAFAMIDIS MEGLUMINE)Orphan drug

Pfizer Laboratories Div Pfizer Inc

FDA label ↗

WAINUA

(EPLONTERSEN)Orphan drug

AstraZeneca Pharmaceuticals LP

FDA label ↗

Onpattro

(PATISIRAN)Orphan drug

Alnylam Pharmaceuticals, Inc.

FDA label ↗

AMVUTTRA

(VUTRISIRAN)Orphan drug

Alnylam Pharmaceuticals, Inc.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Hereditary ATTR amyloidosis.
Search all trials →
Search clinical trials for Hereditary ATTR amyloidosis

Recent News & Research

1 article
AlnylamFeb 5, 2026

Alnylam Reports Record $2.8B Revenue from RNAi Portfolio

Alnylam reported $2.8 billion from RNA interference therapies for hereditary ATTR and other rare diseases.

Read ↗

Browse all Hereditary ATTR amyloidosis news →

Specialist Network

Top 6 by expertise

View all Hereditary ATTR amyloidosis specialists →

Quick Actions